8-K Announcements
6Material company update
May 12, 2026·SEC
Material company update
May 12, 2026·SEC
Material company update
Apr 2, 2026·SEC
Coya Therapeutics, Inc.(COYA)Earnings, Financials & Key Ratios
COYA•NASDAQ
$5.50
Price updated Jun 27, 2026
AboutCoya Therapeutics, Inc., a clinical-stage biotechnology company, develops proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company's product candidates in IND-enabling studies include COYA 301, a Treg-enhancing biologic for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous and/or intravenous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases. It is also developing COYA 201, an allogeneic Treg exosome product candidate that is in preclinical stage for use in the treatment of neurodegenerative, autoimmune, and metabolic diseases; and COYA 206, an antigen directed Treg-derived exosome product candidate, which is in discovery stage. The company was incorporated in 2020 and is headquartered in Houston, Texas.Show more
- Revenue$8M+123.6%
- EBITDA-$20M-17.5%
- Net Income-$21M-42.6%
- EPS (Diluted)-1.27-29.6%
- Gross Margin99.66%+142.6%
- EBITDA Margin-254.71%+47.4%
- Operating Margin-255.05%+47.5%
- Net Margin-267.14%+36.2%
- ROE-51.39%-29.9%
COYA Price & Volume
Coya Therapeutics, Inc. (COYA) stock price & volume — 10-year historical chart
Loading chart...
Milestone Dependency Masks Underlying Clinical Burn Rate
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Mixed
Profitability:Negative
Financial Position:Vulnerable
Cash Flow:Burning
Primary Risk:Clinical Trial Execution Failure
"Coya Therapeutics operates as a research-intensive biotechnology firm whose financial stability is tethered to volatile, milestone-driven revenue rather than recurring product sales. While the company maintains a cash position of $46.8M as of 2026Q1, the persistent negative operating margins and an accumulated deficit of $69.2B highlight the significant execution risks inherent in its clinical pipeline. Investors should monitor the company's ability to secure non-dilutive funding, as the current reliance on sporadic partnership inflows may necessitate future equity dilution to sustain operations."
Verdict Logic
the company's reliance on sporadic milestone payments to offset a $7.6M operating loss in 2026Q1 suggests a high-risk profile that may lead to further shareholder dilution.
COYA Growth Metrics
Coya Therapeutics, Inc. (COYA) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM115.44%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-23.29%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-7.48%
Return on Capital
10 Years-77.43%
5 Years-90.41%
3 Years-43.88%
Last Year-47.91%
COYA Recent Earnings
Coya Therapeutics, Inc. (COYA) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 5/12 qtrs (42%)●Beat Revenue 4/12 qtrs (50%)
Q2 2026Latest
May 12, 2026Metric
Actual
Est
EPS
$0.32+17.9%
$0.39
Rev
$300,000+100.0%
$150,000
Q2 2026
Mar 16, 2026Metric
Actual
Est
EPS
$0.34-24.8%
$0.27
Rev
$4M+78.0%
$2M
Q4 2025
Nov 12, 2025Metric
Actual
Est
EPS
$0.10-600.0%
$0.02
Rev
$4M+85.1%
$2M
Q3 2025
Aug 12, 2025Metric
Actual
Est
EPS
$0.36-63.6%
$0.22
Rev
$163,616-79.1%
$783,333
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 12, 2026 | $0.32vs $0.39+17.9% | $300,000vs $150,000+100.0% |
| Q2 2026 | Mar 16, 2026 | $0.34vs $0.27-24.8% | $4Mvs $2M+78.0% |
| Q4 2025 | Nov 12, 2025 | $0.10vs $0.02-600.0% | $4Mvs $2M+85.1% |
| Q3 2025 | Aug 12, 2025 | $0.36vs $0.22-63.6% | $163,616vs $783,333-79.1% |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Coya Therapeutics, Inc. (COYA)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $5.50 | $100.15M | -4.33 | 123.57% | -267.14% | -51.39% | — | |
| $3.73 | $64.48M | -2.78 | — | -1070.26% | — | — | |
| $1.42 | $37.75M | -0.76 | 257.14% | — | -170.86% | — | |
| $327.79 | $9.47B | -24.32 | -100% | — | -43.02% | — | |
| $2.56 | $260.54M | -2.96 | -86.92% | -1971.7% | -101.76% | — | |
| $1.32 | $63.77M | -2.54 | — | — | -95.77% | — |
Compare COYA vs Peers
Coya Therapeutics, Inc. (COYA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
COYA SEC Filings & Documents
Coya Therapeutics, Inc. (COYA) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when COYA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
COYA Frequently Asked Questions
Coya Therapeutics, Inc. (COYA) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Coya Therapeutics, Inc.'s revenue?
Coya Therapeutics, Inc. (COYA) reported $7.9M in revenue for fiscal year 2025.
How fast is Coya Therapeutics, Inc. growing?
Coya Therapeutics, Inc. (COYA) grew revenue by 123.6% over the past year. This is strong growth.
Is COYA profitable?
Coya Therapeutics, Inc. (COYA) reported a net loss of $21.1M for fiscal year 2025.
Dividend & Returns
What is COYA's return on equity?
Coya Therapeutics, Inc. (COYA) has a return on equity (ROE) of -51.4%. Negative ROE indicates the company is unprofitable.
What is Coya Therapeutics, Inc.'s free cash flow?
Coya Therapeutics, Inc. (COYA) had negative free cash flow of $14.1M in fiscal year 2025, likely due to heavy capital investments.